Testicular shielding in penile brachytherapy.

PURPOSE: Penile cancer, although rare, is one of the common genitourinary cancers in India affecting mostly aged uncircumcised males. For patients presenting with small superficial lesions < 3 cm restricted to glans, surgery, radical external radiation or brachytherapy may be offered, the latter being preferred as it allows organ and function preservation. In patients receiving brachytherapy, testicular morbidity is not commonly addressed. With an aim to minimize and document the doses to testis after adequate shielding during radical interstitial brachytherapy for penile cancers, we undertook this study in 2 patients undergoing brachytherapy and forms the basis of this report. MATERIAL AND METHODS: Two patients with early stage penile cancer limited to the glans were treated with radical high-dose-rate (HDR) brachytherapy using interstitial implant. A total of 7-8 tubes were implanted in two planes, parallel to the penile shaft. A total dose of 44-48 Gy (55-60 Gy EQD2 doses with α/ß = 10) was delivered in 11-12 fractions of 4 Gy each delivered twice daily. Lead sheets adding to 11 mm (4-5 half value layer) were interposed between the penile shaft and scrotum. The testicular dose was measured using thermoluminescent dosimeters. For each patient, dosimetry was done for 3 fractions and mean calculated. RESULTS: The cumulative testicular dose to left and right testis was 31.68 cGy and 42.79 cGy for patient A, and 21.96 cGy and 23.28 cGy for patient B. For the same patients, the mean cumulative dose measured at the posterior aspect of penile shaft was 722.15 cGy and 807.72 cGy, amounting to 16.4% and 16.8% of the prescribed dose. Hence, the application of lead shield 11 mm thick reduced testicular dose from 722-808 cGy to 21.96-42.57 cGy, an "absolute reduction" of 95.99 ± 1.5%. CONCLUSIONS: With the use of a simple lead shield as described, we were able to effectively reduce testicular dose from "spermicidal" range to "oligospermic" range with possible reversibility.

Estimation of dose enhancement to soft tissue due to backscatter radiation near metal interfaces during head and neck radiothearpy - A phantom dosimetric study with radiochromic film.

The objective of this study was to investigate the dose enhancement to soft tissue due to backscatter radiation near metal interfaces during head and neck radiotherapy. The influence of titanium-mandibular plate with the screws on radiation dose was tested on four real bones from mandible with the metal and screws fixed. Radiochromic films were used for dosimetry. The bone and metal were inserted through the film at the center symmetrically. This was then placed in a small jig (7 cm × 7 cm × 10 cm) to hold the film vertically straight. The polymer granules (tissue-equivalent) were placed around the film for homogeneous scatter medium. The film was irradiated with 6 MV X-rays for 200 monitor units in Trilogy linear accelerator for 10 cm × 10 cm field size with source to axis distance of 100 cm at 5 cm. A single film was also irradiated without any bone and metal interface for reference data. The absolute dose and the vertical dose profile were measured from the film. There was 10% dose enhancement due to the backscatter radiation just adjacent to the metal-bone interface for all the materials. The extent of the backscatter effect was up to 4 mm. There is significant higher dose enhancement in the soft tissue/skin due to the backscatter radiation from the metallic components in the treatment region.

Phantom dosimetric study of nondivergent aluminum tissue compensator using ion chamber, TLD, and gafchromic film.

Anatomic contour irregularity and tissue inhomogeneity in head-and-neck radiotherapy can lead to significant dose inhomogeneity due to the presence of hot and cold spots across the treatment volumes. Missing tissue compensators (TCs) can overcome this dose inhomogeneity. The current study examines the capacity of 2-dimensional (2D) custom aluminum TCs fabricated at our hospital to improve the dose homogeneity across the treatment volume. The dosimetry of the 2D custom TCs was carried out in a specially designed head-and-neck phantom for anterior-posterior (AP) and posterior-anterior (PA) fields with an ion chamber, thermoluminscence dosimeters (TLDs), and film. The results were compared for compensated and uncompensated plans generated from the Eclipse treatment planning system. On average, open-field plans contained peak doses of 117%, optimally wedged-plans contained peak doses of 113%, and custom-compensated plans contained peak doses of 105%. The dose variation between prescribed and measured dose at midplane of the phantom was observed as high as 17%, which was reduced to 3.2% for the customized TC during ionometric measurements. It was further confirmed with TLDs, in a sagittal plane, that the high-dose region of 13.3% was reduced to 2.3%. The measurements carried out with the ion chamber, TLDs, and film were found in good agreement with each other and with Eclipse. Thus, a custom-made 2D TC is capable of reducing hot spots to improve overall dose homogeneity across the treatment volume.

Estimation of risk of radiation-induced carcinogenesis in adolescents with nasopharyngeal cancer treated using sliding window IMRT.

PURPOSE: To estimate the risk of radiation-induced carcinogenesis based on whole-body dose measurement on adolescent patients undergoing intensity-modulated radiotherapy (IMRT). METHODS AND MATERIALS: Ten adolescent patients with nasopharyngeal cancer were planed and treated to a dose of 70.2 Gy using sliding window IMRT. Peripheral dose (PD) was measured using thermoluminescent dosimeters kept at anterior, lateral and posterior positions of each axial plane at the level of xiphoid process, umbilicus and gonads of every patient. The associated risk of radiation-induced carcinogenesis was estimated based on the measured whole-body dose and using age- and sex-specific ICRP-60 nominal probability coefficient of 7.5% (boys) and 9.5% (girls) per Sv. RESULTS: In all patients, measured PD per monitor unit (MU) decreases almost exponentially with out-of-field distance and varies with gantry angle. Highest whole-body dose equivalent ranged from 0.5318 to 0.9867 Sv (mean=0.8141 Sv, SD=0.138) which was measured posteriorly at the level of xiphoid process. Whole-body dose was represented by the average dose at xiphoid process and all measurement positions ranged from 0.3661 to 0.8766 Sv (mean=0.658 Sv, SD=0.16) and 0.2267 to 0.5277 Sv (mean=0.3859 Sv, SD=0.09), respectively. The associated mean risk of radiation-induced carcinogenesis estimated based on different representation of mean whole-body dose was 6.57%, 5.3% and 3.11%, respectively. Higher mean risk of 7.32% was estimated among girls as compared to 6.25% for boys. CONCLUSIONS: Knowledge of risk of secondary malignancy is particularly important in adolescents and should be considered when choosing the optimal treatment technique and delivery system.

On the transit dose from motorized wedge treatment in Equinox-80 telecobalt unit.

PURPOSE: To estimate the transit dose from motorized wedge (MW) treatment in Equinox-80 telecobalt machine. MATERIALS AND METHODS: Two plans were generated in Eclipse treatment planning system with universal wedge (UW) and MW each for 10 x 10 cm 2 . The transit dose was measured with 0.6 cc cylindrical ion chamber and thermoluminescent dosimeters (TLD) chips at a depth of 5 cm with source to axis distance (SAD) 80 cm. RESULTS: The measured dose with ion chamber was in well agreement with the calculated dose from Eclipse within +/- 2%. The planned dose was 100 cGy while the measured absorbed dose with ion chamber for 15 degrees , 30 degrees , 45 degrees and 60 degrees MW treatment was found to be 100.94, 101.04, 100.72 and 99.33 cGy respectively. For 15 degrees , 30 degrees , 45 degrees and 60 degrees UW treatment, the measured absorbed dose was 99.33, 97.67, 97.77 and 99.57 cGy respectively. Similarly the measured absorbed dose with TLD was within +/- 3% with the planned dose for universal wedge (UW) and MW. From the experimental measurements, it was found that there was no significant contribution of transit dose during MW treatment. CONCLUSION: The actual measurements carried out with ion chamber in Equinox-80 machine for UW and MW revealed no variation between the doses delivered. The doses were comparable for both UW and MW treatments. The results from TLD measurements additionally confirmed no variation between the doses delivered with UW and MW. It was also demonstrated that the observed excess or less transit dose with MW does not have any significant clinical impact. This assured the safe dose delivery with MW.

Electronic tissue compensation achieved with both dynamic and static multileaf collimator in eclipse treatment planning system for Clinac 6 EX and 2100 CD Varian linear accelerators: Feasibility and dosimetric study.

Dynamic multileaf collimator (DMLC) and static multileaf collimator (SMLC), along with three-dimensional treatment planning system (3-D TPS), open the possibility of tissue compensation. A method using electronic tissue compensator (ETC) has been implemented in Eclipse 3-D TPS (V 7.3, Varian Medical Systems, Palo Alto, USA) at our center. The ETC was tested for head and neck conformal radiotherapy planning. The purpose of this study was to verify the feasibility of DMLC and SMLC in head and neck field irradiation for delivering homogeneous dose in the midplane at a pre-defined depth. In addition, emphasis was given to the dosimetric aspects in commissioning ETC in Eclipse. A Head and Neck Phantom (The Phantom Laboratory, USA) was used for the dosimetric verification. Planning was carried out for both DMLC and SMLC ETC plans. The dose calculated at central axis by eclipse with DMLC and SMLC was noted. This was compared with the doses measured on machine with ion chamber and thermoluminescence dosimetry (TLD). The calculated isodose curves and profiles were compared with the measured ones. The dose profiles along the two major axes from Eclipse were also compared with the profiles obtained from Amorphous Silicon (AS500) Electronic portal imaging device (EPID) on Clinac 6 EX machine. In uniform dose regions, measured dose values agreed with the calculated doses within 3%. Agreement between calculated and measured isodoses in the dose gradient zone was within 3 mm. The isodose curves and the profiles were found to be in good agreement with the measured curves and profiles. The measured and the calculated dose profiles along the two major axes were flat for both DMLC and SMLC. The dosimetric verification of ETC for both the linacs demonstrated the feasibility and the accuracy of the ETC treatment modality for achieving uniform dose distributions. Therefore, ETC can be used as a tool in head and neck treatment planning optimization for improved dose uniformity.

Characterizing and configuring motorized wedge for a new generation telecobalt machine in a treatment planning system.

A new generation telecobalt unit, Theratron Equinox-80, (MDS Nordion, Canada) has been evaluated. It is equipped with a single 60-degree motorized wedge (MW), four universal wedges (UW) for 15°, 30°, 45° and 60°. MW was configured in Eclipse (Varian, Palo Alto, USA) 3D treatment planning system (TPS). The profiles and central axis depth doses (CADD) were measured with radiation field analyzer blue water phantom for MW. These profiles and CADD for MW were compared with UW in a homogeneous phantom generated in Eclipse for various field sizes. The absolute dose was measured for a field size of 10 × 10 cm2 only in a MEDTEC water phantom at 10 cm depth with a 0.13 cc thimble ion chamber (Scanditronix Wellhofer, Uppsala, Sweden) and a NE electrometer (Nuclear Enterprises, UK). Measured dose with ion chamber was compared with the TPS predicted dose. MW angle was verified on the Equinox for four angles (15°, 30°, 45° and 60°). The variation in measured and calculated dose at 10 cm depth was within 2%. The measured and the calculated wedge angles were in well agreement within 2°. The motorized wedges were successfully configured in Eclipse for four wedge angles.

Clinical application of a OneDose MOSFET for skin dose measurements during internal mammary chain irradiation with high dose rate brachytherapy in carcinoma of the breast.

In our earlier study, we experimentally evaluated the characteristics of a newly designed metal oxide semiconductor field effect transistor (MOSFET) OneDose in-vivo dosimetry system for Ir-192 (380 keV) energy and the results were compared with thermoluminescent dosimeters (TLDs). We have now extended the same study to the clinical application of this MOSFET as an in-vivo dosimetry system. The MOSFET was used during high dose rate brachytherapy (HDRBT) of internal mammary chain (IMC) irradiation for a carcinoma of the breast. The aim of this study was to measure the skin dose during IMC irradiation with a MOSFET and a TLD and compare it with the calculated dose with a treatment planning system (TPS). The skin dose was measured for ten patients. All the patients' treatment was planned on a PLATO treatment planning system. TLD measurements were performed to compare the accuracy of the measured results from the MOSFET. The mean doses measured with the MOSFET and the TLD were identical (0.5392 Gy, 15.85% of the prescribed dose). The mean dose was overestimated by the TPS and was 0.5923 Gy (17.42% of the prescribed dose). The TPS overestimated the skin dose by 9% as verified by the MOSFET and TLD. The MOSFET provides adequate in-vivo dosimetry for HDRBT. Immediate readout after irradiation, small size, permanent storage of dose and ease of use make the MOSFET a viable alternative for TLDs.

Dosimetric evaluation of a new OneDose MOSFET for Ir-192 energy.

The purpose of this study was to investigate dosimetry (reproducibility, energy correction, relative response with distance from source, linearity with threshold dose, rate of fading, temperature and angular dependence) of a newly designed OneDosetrade mark MOSFET patient dosimetry system for use in HDR brachytherapy with Ir-192 energy. All measurements were performed with a MicroSelectron HDR unit and OneDose MOSFET detectors. All dosimeters were normalized to 3 min post-irradiation to minimize fading effects. All dosimeters gave reproducible readings with mean deviation of 1.8% (SD 0.4) and 2.4% (SD 0.6) for 0 degrees and 180 degrees incidences, respectively. The mean energy correction factor was found to be 1.1 (range 1.06-1.12). Overall, there was 60% and 40% mean response of the MOSFET at 2 and 3 cm, respectively, from the source. MOSFET results showed good agreement with TLD and parallel plate ion chamber. Linear dose response with threshold voltage shift was observed with applied doses of 0.3 Gy-5 Gy with Ir-192 energy. Linearity (R2 = 1) was observed in the MOSFET signal with the applied dose range of 0.3 Gy-5 Gy with Ir-192 energy. Fading effects were less than 1% after 10 min and the MOSFET detectors stayed stable (within 5%) over a period of 1 month. The MOSFET response was found to be decreased by approximately 1.5% at 37 degrees C compared to 20 degrees C. The isotropic response of the MOSFET was found to be within +/-6%. A maximum deviation of 5.5% was obtained between 0 degrees and 180 degrees for both the axes and this should be considered in clinical applications. The small size, cable-less, instant readout, permanent storage of dose and ease of use make the MOSFET a novel dosimeter and beneficial to patients for skin dose measurements with HDRBT using an Ir-192 source compared to the labour demanding and time-consuming TLDs.

Effect of tertiary multileaf collimator (MLC) on foetal dose during three-dimensional conformal radiation therapy (3DCRT) of a brain tumour during pregnancy.

BACKGROUND AND PURPOSE: The aim of this work was to measure the dose to foetus both in vivo and in vitro during three-dimensional conformal radiation therapy (3DCRT) in a pregnant patient with a pituitary adenoma. The study was then extended to assess the components contributing to the foetal dose such as collimator scatter, internal scatter, head leakage, wedge scatter and multileaf collimator (MLC) effect. PATIENTS AND METHODS: A 30-year-old pregnant woman with a non-functioning pituitary macroadenoma was planned for 3DCRT with 6MV X-ray using four equally weighted MLC-shaped non-coplanar wedged portals. In vivo dosimetry was carried out using thermoluminescent (TL) phosphor powder, which was placed at different positions on the patient, corresponding to different locations in the uterus and also at external os. In vitro measurements were also performed on a simulated phantom using the same set-up parameters and beam arrangement to verify the in vivo measured dose. Experiments were carried out to measure the respective contributions of different components towards peripheral dose. RESULTS: In vitro measured dose to foetus was found to be slightly more than that of in vivo measurement with a maximum of 0.044% of the prescribed dose of 45Gy, which corresponded to 0.0199+/-0.0008Gy. Thermoluminescence dosimeter (TLD) kept at the external os of the patient showed a dose of 0.031% of the prescribed dose. Among the various components of the peripheral dose (foetal dose) measured, head leakage was found to be the leading cause contributing 52%, followed by wedge scatter (31%), collimator scatter (14%) and internal scatter (13%). The use of MLC reduced not only the volume of normal brain irradiation as compared to open fields but also the peripheral dose by 10%. CONCLUSION: Radiotherapy of brain tumours during pregnancy poses a unique clinical situation and decisions to deliver radiotherapy should be taken after detailed in vitro and in vivo dosimetric measurements. Our findings suggest that the beam arrangement using 3-4-fields generally used for 3DCRT of brain tumour with MLC for optimal coverage can be employed for pregnant patients even in early trimester. A possible increase in foetal dose from wedges to a large extent can be compensated with the use of MLC.